Antibiotics, also known as antibacterials, are medications that destroy or slow down growth of bacteria in the body. Antibiotics include a range of powerful drugs, which are used to treat diseases caused by bacteria. Antibiotics can be a lifesaving treatment for children with bacterial infections and are the most commonly prescribed therapy among all medications given to children. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs.
Global pediatric antibiotics market is estimated to be valued at US$ 6,478.9 million in 2022 and is expected to exhibit a CAGR of 2.3% during the forecast period (2022-2030).
Figure 1.Global Pediatric Antibiotics Market Share (%) in Terms of Value, By Route of Administration, 2022
Increasing adoption of inorganic growth strategies by key players is expected to drive market growth during the forecast period.
Increasing adoption of inorganic growth strategies such as collaboration by key players for development of pediatric antibiotics is expected to drive the global pediatric antibiotics market growth over the forecast period. For instance, in April 2020, Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company, and the Global Antibiotic Research and Development Partnership (GARDP), a not-for-profit research and development (R&D) organization, announced a collaboration to accelerate development of, and access to, cefepime-taniborbactam (formerly cefepime/VNRX-5133). Cefepime-taniborbactam is an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). GARDP will collaborate with Venatorx to complete development of cefepime-taniborbactam, which includes a phase 3 complicated urinary tract infection (cUTI) trial.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 6,478.9 Mn |
| Historical Data for: | 2017-2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 2.3% | 2030 Value Projection: | US$ 7,759.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Johnson & Johnson, Astellas Pharma, Inc, Pfizer Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Abbott., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GlaxoSmithKline Plc., Hikma Pharmaceuticals PLC, Cipla Inc., Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Pediatric Antibiotics Market Share (%), By Distribution Channel, 2022
Surge in prevalence of bacterial infections among children is expected to drive market growth during the forecast period.
Surge in prevalence of bacterial infections among children is expected to drive global pediatric antibiotics market growth during the forecast period. For instance, according to data published by, UpToDate, Inc. a software system that is a point-of-care medical resource in July 2021, the overall prevalence of Urinary tract infections (UTI) is approximately 7% in febrile infants and young children but varies by age, sex, and circumcision status globally.
Global Pediatric Antibiotics Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 535.8 million infected individuals worldwide as of June 17 2022.
COVID-19 had affected the economy in three main ways; by directly affecting production and demand of pediatric antibiotics, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others faced problems with regard to transportation of drugs from one place to another.
Furthermore, players operating in the global pediatric antibiotics market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19
Global Pediatric Antibiotics Market: Restraint
The major factors that hinder growth of the global pediatric antibiotics market include side effects caused due to adverse reaction of certain antibiotics and stringent regulations for the use of antibiotics in pediatrics. Common side effects of antibiotics in pediatrics include diarrhea, allergic reaction which occurs when the immune system overreacts to something it views as dangerous, drug-related rash, yeast infection, stained teeth, and fever. Some severe side effects include anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, muscle pain, red man syndrome etc.
Key Players
Key players operating in market include Johnson & Johnson, Astellas Pharma, Inc, Pfizer Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Abbott., DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma USA, GlaxoSmithKline Plc., Hikma Pharmaceuticals PLC, Cipla Inc., Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd.
Antibiotics are used to treat or prevent some types of bacterial infection. Antibiotics work by killing bacteria or preventing them from reproducing and spreading. Antibiotics are the most commonly prescribed drugs in children and have the potential to save the lives of patients with severe bacterial infections such as Non-Specific Upper Respiratory Tract Infections, Urinary Tract Infections etc. They are taken orally and come in the form of tablets, liquid suspension, and capsules. Antibiotics are also administered through the intravenous route. Antibiotics are available in the form of ointments, creams, lotions, etc. for topical administration.
Market Dynamics
Key players operating in the global pediatric antibiotics market are focusing on adoption of growth strategies such as product approval, which is expected to drive market growth during the forecast period. For instance, in January 2020, Merck a leading global biopharmaceutical company known as MSD outside of the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved a New Drug Application (NDA) for DIFICID (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older. Moreover, increasing demand of pediatric antibiotics is expected to propel market growth over the forecast period. For instance, in 2021, United Nations International Children's Emergency Fund (UNICEF) delivered 31.6 million antibiotic treatments to children under one year of age in 54 countries.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients